Stock Ratings / Health Care / DBVT / forecast

AURA (40) SLBT (47) CADL (38) IAM (50) ⌘ Pro Terminal →

DBV Technologies S.A. (DBVT) 12-Month Stock Forecast & Price Target Cone

$10.29 -3.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.21

DBV Technologies S.A. (DBVT) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $647.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.21 (-0.80%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for DBVT)Realized 20D OHLCV Swing Band: ±12.1%

Deterministic 5-Pillar Attribution (26/100 Composite)

🔍 WHY DBVT SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+7/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.1% realized swing band)

▲ #2 Bullish Driver: Cash Engine Quality+6/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$9.80-7.7% Next Q

Q2 (-2Q)

Grade E$9.05+7.7% Next Q

Q3 (-1Q)

Grade E$9.75+5.5% Next Q

Current

Grade E$10.29-10.5% Hist 90D α

Trajectory: E (18) → E (26)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a DBVT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While DBVT currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.53) and Max Pain ($10.80) forces dealer call-delta covering toward $27.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $DBVT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “DBVT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 26%NO 74%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your DBVT Position Size: $10,000

Shares at $10.29: 971.8 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $6.87

$6,676

$-3,324 (-33.2%)

12M Consensus BaseTarget $8.81

$8,562

$-1,438 (-14.4%)

12M Bull Case BreakoutTarget $27.50

$26,725

+$16,725 (+167.2%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$9	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$26	69%	B
JP MorganUS Large-Cap Research	SELL	$8	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring DBVT)

✓Walkthrough of DBVT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

DBVT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -51.00%⚡ TESTING RESISTANCE

2026-10-30O $9.96H $10.29L $9.33C $10.29VOL 410.6K

RES: $10.67SUP: $7.82SMA50: $11.53SMA200: $16.95

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

DBVT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 DBVT Butterfly Map → + Track DBVT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +35.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on DBVT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for DBVT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for DBVT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (DBVT)

Health Care Rank #985 of 1016 ⚔️ AURA vs DBVT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (DBVT vs. AURA, SLBT, CADL, IAM)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, DBV Technologies S.A. (DBVT) ranks #985 by composite RQD confidence (26/100, grade E) and #412 by equity capitalization ($647.0M). Within this direct 5-issuer industry benchmark cohort, DBVT leads on earnings valuation at N/A trailing P/E, while DBVT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with DBVT at 26/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
DBVT ACTIVE DBV Technologies S.A.	E	26/100	—	—	-35.0%	-3.38%	$647.0M	Benchmark Subject
AURA Aura Biosciences Inc.	D-	40/100	—	—	-35.0%	-1.64%	$652.8M	/aura-vs-dbvt →
SLBT SL Science Holding Limited	D	47/100	—	—	—	-3.31%	$656.1M	/slbt-vs-dbvt →
CADL Candel Therapeutics Inc.	D-	38/100	—	—	-35.0%	-0.23%	$661.9M	/cadl-vs-dbvt →
IAM Iambic Therapeutics Inc.	D	50/100	—	—	—	-3.38%	$676.9M	/iam-vs-dbvt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001613780

In its most recent audited fiscal period (FY2025, filed 2025-12-31), DBV Technologies S.A. (DBVT) reported GAAP revenue of $5.6M (+35.8% vs. FY2024 revenue of $4.2M , and -64.2% cumulative change since FY2023) , GAAP net income of -$146.9M, operating cash flow of -$121.2M, and free cash flow of -$121.7M (-14.0% YoY). On the balance sheet, DBVT closed FY2025 with $233.7M in total assets against $0 in total debt (Altman Z-Score: 2.37, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$5.6M	-$146.9M	-$121.2M	-$121.7M	$233.7M	—
FY2024 (FY)	2024-12-31	$4.2M	-$113.9M	-$104.5M	-$106.8M	$65.7M	—
FY2023 (FY)	2023-12-31	$15.7M	-$72.7M	-$79.7M	-$79.7M	—	—

3. DBVT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is DBVT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, DBV Technologies S.A. (NASDAQ: DBVT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $10.29 (-3.38% 1D, market cap $647.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 4/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, DBVT ranks #985 in composite RQD confidence.

How does DBVT compare to AURA and SLBT in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), DBVT carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, AURA (Aura Biosciences Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $652.8M) and SLBT (SL Science Holding Limited) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $656.1M). Among the 5-stock peer group, DBVT leads on earnings multiple (N/A) while DBVT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for DBVT?

Per DBVT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001613780), DBV Technologies S.A. generated $5.6M in revenue (+35.8% YoY), -$146.9M in net income, and -$121.7M in free cash flow against $233.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is DBVT trading relative to its 50-day, 200-day, and 52-week technical levels?

DBVT last traded at $10.29 (-3.38% on volume of 1,033,828 shares), positioning the stock -10.75% below its 50-day simple moving average ($11.53) and -39.29% below its 200-day simple moving average ($16.95). Across its 52-week range of $8.63 to $26.19, DBVT sits at the 9.5% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.1% ($9.04 to $11.54).

DBVT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is DBVT's 12-month stock price target?

DBV Technologies S.A. (DBVT) carries a 12-month consensus base price target of $8.81 (-14.4% from $10.29), with a bull-case target of $27.5 and a bear-case floor of $6.87.

Is DBVT stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates DBVT E (Strong Sell — SELL) with an RQD Confidence score of 26/100.

Direct Sub-Reports: DBVT RQD Cockpit DBVT 12M Forecast DBVT Earnings & Move DBVT Dividends & DRIP DBVT Insiders & 13F DBVT Whale Options DBVT Profit Sankey DBVT News & Why